Fairtree Asset Management Pty Ltd Increases Position in Zoetis Inc. $ZTS

Fairtree Asset Management Pty Ltd lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 82.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,265 shares of the company’s stock after purchasing an additional 13,194 shares during the quarter. Zoetis comprises approximately 1.7% of Fairtree Asset Management Pty Ltd’s portfolio, making the stock its 15th biggest position. Fairtree Asset Management Pty Ltd’s holdings in Zoetis were worth $3,682,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC grew its holdings in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Glenview Trust co lifted its holdings in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after buying an additional 506 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ZTS shares. Citigroup cut their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Stifel Nicolaus set a $105.00 price target on Zoetis in a research report on Friday, May 8th. Finally, UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $134.75.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $78.89 on Wednesday. The business has a fifty day moving average of $110.54 and a 200-day moving average of $119.82. The firm has a market cap of $33.07 billion, a PE ratio of 13.08, a price-to-earnings-growth ratio of 1.27 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the firm posted $1.48 earnings per share. The company’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Insider Transactions at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 11,650 shares of company stock worth $886,384 over the last 90 days. 0.22% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.